During the American Society of Clinical Oncology (ASCO) 2020 Meeting, the Multiple Myeloma Hub was pleased to speak to Enrique M. Ocio, Marqués de Valdecilla University Hospital, Santander, ES. In this podcast, Enrique M. Ocio discusses the results of the phase I/II trial that evaluated quadruplet combinations in patients with transplant-ineligible multiple myeloma.

Enrique M. Ocio begins by describing how first-line treatments for this population of patients have changed recently, and then provides results from a study investigating the use of isatuximab (an anti-CD8 monoclonal antibody) in combination with quadruplet regimens; bortezomib + cyclophosphamide + dexamethasone (VCd) or bortezomib + lenalidomide + dexamethasone (VRd). He provides efficacy, safety and tolerably data as well as measurable residual disease analysis, and concludes with his perspective on which treatments should be used for elderly patients.

Hosted on Acast. See acast.com/privacy for more information.